US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two Phase III studies evaluating the once-weekly GIP receptor and GLP-1 receptor agonist, Mounjaro (tirzepatide), as a treatment for obesity. The studies showed that tirzepatide achieved up to 26.6% mean weight loss over durations of either 88 weeks or 72 weeks.
SURMOUNT-3 and SURMOUNT-4 Studies Expand on Positive Data
The two studies, SURMOUNT-3 (72 weeks) and SURMOUNT-4 (88 weeks), included a combined 1,249 randomized adults without diabetes, in addition to the over 3,400 patients in SURMOUNT-1 and SURMOUNT-2. Positive data from these earlier studies has already been published by Lilly. These additional trials further solidify the evidence base for tirzepatide’s efficacy in treating obesity.
Upcoming FDA Decision on Tirzepatide for Obesity Treatment
The US FDA is anticipated to make a decision on tirzepatide’s use in treating obesity in people with or without diabetes later this year. This decision will be a significant milestone for the drug’s application in the broader weight loss market. Tirzepatide was previously approved in the US in May 2022 for the treatment of type 2 diabetes, marking a step forward in the management of this condition.-Fineline Info & Tech
